Loading
A year of pembrolizumab after surgery for stage IIB or IIC melanoma reduced recurrences and distant metastases by about 35 to 40 percent, extending adjuvant immunotherapy to node-negative but thick or ulcerated melanomas.
Phase 3 placebo-controlled trial of 976 patients aged 12 and over with resected stage IIB or IIC melanoma randomised to pembrolizumab or placebo for up to 17 cycles.
At the first interim analysis, recurrence-free survival favoured pembrolizumab (hazard ratio 0.65); at longer follow-up, 36-month recurrence-free survival was 76.2 versus 63.4 percent and distant metastasis-free survival hazard ratio 0.59. Immune-related adverse events, mainly endocrine, occurred in about a third.
Adjuvant pembrolizumab is approved for stage IIB and IIC melanoma, though the absolute benefit and lack of survival data make observation a reasonable alternative after discussion.
Shares KEYNOTE-716, Stage IIB and IIC melanoma, Pembrolizumab.
Shares KEYNOTE-716, Stage IIB and IIC melanoma.
Shares The Lancet, Pembrolizumab.
Shares The Lancet, Pembrolizumab.
Shares The Lancet, Pembrolizumab.
Shares The Lancet, Pembrolizumab.
Shares The Lancet, Pembrolizumab.
Shares Stage IIB and IIC melanoma, Pembrolizumab.